Your browser doesn't support javascript.
loading
Intramyocellular Triglyceride Content During the Early Course of Type 1 and Type 2 Diabetes.
Schön, Martin; Zaharia, Oana P; Strassburger, Klaus; Kupriyanova, Yuliya; Bódis, Kálmán; Heilmann, Geronimo; Strom, Alexander; Bönhof, Gidon J; Michelotti, Filippo; Yurchenko, Iryna; Möser, Clara; Huttasch, Maximilian; Bombrich, Maria; Kelm, Malte; Burkart, Volker; Schrauwen-Hinderling, Vera B; Wagner, Robert; Roden, Michael.
Afiliação
  • Schön M; Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Zaharia OP; German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany.
  • Strassburger K; Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Kupriyanova Y; German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany.
  • Bódis K; Department of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Heilmann G; German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany.
  • Strom A; Institute for Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Bönhof GJ; Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Michelotti F; German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany.
  • Yurchenko I; Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Möser C; German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany.
  • Huttasch M; Department of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Bombrich M; Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Kelm M; German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany.
  • Burkart V; Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Schrauwen-Hinderling VB; German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany.
  • Wagner R; Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Roden M; German Center for Diabetes Research, Partner Düsseldorf, München-Neuherberg, Germany.
Diabetes ; 72(10): 1483-1492, 2023 10 01.
Article em En | MEDLINE | ID: mdl-37478166
ABSTRACT
Intramyocellular lipid content (IMCL) is elevated in insulin-resistant humans, but it changes over time, and relationships with comorbidities remain unclear. We examined IMCL during the initial course of diabetes and its associations with complications. Participants of the German Diabetes Study (GDS) with recent-onset type 1 (n = 132) or type 2 diabetes (n = 139) and glucose-tolerant control subjects (n = 128) underwent 1H-MRS to measure IMCL and muscle volume, whole-body insulin sensitivity (hyperinsulinemic-euglycemic clamps; M-value), and cycling spiroergometry (VO2max). Subgroups underwent the same measurements after 5 years. At baseline, IMCL was ∼30% higher in type 2 diabetes than in other groups independently of age, sex, BMI, and muscle volume. In type 2 diabetes, the M-value was ∼36% and ∼62% lower compared with type 1 diabetes and control subjects, respectively. After 5 years, the M-value decreased by ∼29% in type 1 and ∼13% in type 2 diabetes, whereas IMCL remained unchanged. The correlation between IMCL and M-value in type 2 diabetes at baseline was modulated by VO2max. IMCL also associated with microalbuminuria, the Framingham risk score for cardiovascular disease, and cardiac autonomic neuropathy. Changes in IMCL within 5 years after diagnosis do not mirror the progression of insulin resistance in type 2 diabetes but associate with early diabetes-related complications. ARTICLE HIGHLIGHTS Intramyocellular lipid content (IMCL) can be elevated in insulin-resistant humans, but its dynamics and association with comorbidities remain unclear. Independently of age, sex, body mass, and skeletal muscle volume, IMCL is higher in recent-onset type 2, but not type 1 diabetes, and remains unchanged within 5 years, despite worsening insulin resistance. A degree of physical fitness modulates the association between IMCL and insulin sensitivity in type 2 diabetes. Whereas higher IMCL associates with lower insulin sensitivity in people with lower physical fitness, there is no association between IMCL and insulin sensitivity in those with higher degree of physical fitness. IMCL associates with progression of microalbuminuria, cardiovascular disease risk, and cardiac autonomic neuropathy.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Doenças Cardiovasculares / Diabetes Mellitus Tipo 1 / Diabetes Mellitus Tipo 2 Limite: Child, preschool / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Doenças Cardiovasculares / Diabetes Mellitus Tipo 1 / Diabetes Mellitus Tipo 2 Limite: Child, preschool / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article